Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 389

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 389
---
shares of Common Stock for exercise prices ranging from $ 704.00per share to $ 9,620.00per share under the 2024 Plan (as defined below). The grants have various vesting conditions, including time-based and performance-based terms. These stock options expire through June 24, 2034. On September 30, 2024 and October 1, 2024, 1,728of these stock options were cancelled due to termination or other reasons. Additionally, on October 1, 2024, the exercise price of the remaining 793outstanding options granted under the 2024 Plan was adjusted to $ 200.00per share, with all other terms of the original grant to remain without adjustment. On October 1, 2024, the Company calculated the total fair value of the consideration for the modification of these stock options, which includes the incremental fair value of the stock options (determined by comparing the fair values immediately prior to and immediately after the modification). The fair values were calculated using the Black-Scholes option-pricing model, and the Company determined that the total fair value of the consideration related to the modification of these stock options amounted to $ 76,027, of which $ 28,636was expensed immediately and $ 47,391will be recorded as stock-based compensation expense over the remaining vesting term. On October 1, 2024, the Company’s Board of Directors granted directors, officers and employees options to purchase up to 2,389shares of common stock for $ 200.00per share. The grants have various vesting conditions, including time-based and performance-based terms. These stock options expire on October 1, 2034. F-57

Predecessor’s Stock
option activity for the period from December 31, 2023 through February 14, 2024 and the Company’s stock option activity for the
period from February 14, 2024 through December 31, 2024, was as follows:

|                                             |     | Outstanding 
 Shares      |        |   |     | Weighted  
 Average   
 Exercise  
 Price Per 
 Share     |          |     | Weighted    
 Average     
 Remaining   
 Contractual 
 Life        
 (in Years)  |      |
|:--------------------------------------------|:----|:------------|-------:|:--|:----|:----------|---------:|:----|:------------|-----:|
| Balance, December 31